Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.5352W HIGH $4.34
Volume
361.86 K
Value Traded
506.25 K
Short % Float
6.82%
-5.56%Week
-6.1%1 Month
-10.28%3 Month
-10.28%6 Month
-83.25%5 Year
-84.14%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
70.48 M
EPS (TTM)
-0.46
P/E Ratio
-
Ent. Value
57.87 M
Total Shares
43.64 M
Float Shares
42.36 M
Insiders
2.93%
Institutions
20.18%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
GANX Catalyst Timeline
Dated clinical, regulatory and corporate events for Gain Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Gain Therapeutics, Inc.
219Total events
11Upcoming
20Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Poster PresentationrexaceractPresentation
Poster presentation of Phase 1b OLE 12-month data for rexaceract at MDS Congress
Parkinson's diseasesource ↗
▲Long Term DatarexaceractClinical Data
12-month open-label extension data showing stabilization of MDS-UPDRS motor scores
Parkinson's diseasesource ↗
▲Safety Data UpdaterexaceractClinical Data
No new safety signals over 12 months of rexaceract dosing; lower TEAE incidence in OLE Part 2 vs Part 1
Parkinson's diseasesource ↗
▲Enrollment CompleterexaceractTrial
12 of 13 evaluable patients completed full 12-month rexaceract administration in OLE
Parkinson's diseasesource ↗
●Enrollment UpdaterexaceractTrial
12 of 13 evaluable patients completed 12-month dosing; one remaining participant
Parkinson's diseasesource ↗
▲Preclinical PoCGT-04686Preclinical
Preclinical evidence of GT-04686 activity presented
Parkinson's diseasesource ↗
▲Enrollment MilestonerexaceractTrial
All 16 participants remained on study at Day 150
Parkinson's diseasesource ↗
▲DSMB ReviewrexaceractTrial
DMC recommended continuation without modification
Parkinson's diseasesource ↗
◆Trial InitiationGT-02287Trial
Initiation of Phase 2a study of GT-02287 expected in 3Q26
Parkinson's diseasesource ↗
▲IND ClearanceGT-02287IND
FDA clearance of IND for GT-02287 Phase 2 in Parkinson's disease
Parkinson's diseasesource ↗
◆Oral PresentationPresentation
Gain Therapeutics to present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
◆Oral PresentationPresentation
Management attendance at 7th World Parkinson’s Congress
Parkinson's diseasesource ↗
◆Oral PresentationGT-02287Presentation
Oral presentation at 3rd International GBA1 Meeting 2026
Parkinson's diseasesource ↗
◆Topline ReadoutGT-02287Clinical Data
Interim data from Phase 1b study extension (Day 150) presented
Parkinson's diseasesource ↗
◆Oral PresentationGT-02287Presentation
Presentation at 3rd International GBA1 Meeting later this month
Parkinson's diseasesource ↗
▲Topline ReadoutGT-02287Clinical Data
Initial results from Phase 1b clinical trial
Parkinson's diseasesource ↗
◆FDA Feedback ReceivedGT-02287FDA Meeting
FDA response expected within weeks after March 2026 IND submission
Parkinson's diseasesource ↗
●Quarterly UpdateCorporate
Cash position of $16.5M as of March 31, 2026; expected to fund into Q2 2027
◆Oral PresentationGT-02287Presentation
Oral presentation of Phase 1b study of GT-02287 at AD/PDTM 2026
Parkinson's diseasesource ↗
●IND Enabling CompleteGT-04686Preclinical
Novel chemical series led by GT-04686 ready for IND-enabling studies
Parkinson's diseasesource ↗
◆Poster PresentationPresentation
Poster presentation on novel allosteric GCase modulators distinct from GT-02287 at AD/PDTM 2026
Parkinson's diseasesource ↗
◆Oral PresentationGT-02287Presentation
Oral presentation of Phase 1b clinical and biomarker data at AD/PD 2026
Parkinson's diseasesource ↗
◆Poster PresentationGT-04686Presentation
Poster presentation of preclinical data for novel chemical series led by GT-04686 at AD/PD 2026
Parkinson's diseasesource ↗
▲Enrollment MilestoneGT-02287Trial
16 of 19 participants from Part 1 enrolled in ongoing nine-month extension (Part 2)
Parkinson's diseasesource ↗
▲DSMB ReviewGT-02287Trial
Data Monitoring Committee meeting concluded study should continue without changes
Parkinson's diseasesource ↗
●IND SubmissionGT-02287IND
IND submitted to FDA for Phase 2 trial of GT-02287
Parkinson's diseasesource ↗
◆Oral PresentationGT-02287Presentation
Additional Phase 1b data presented at AD/PD 2026
Parkinson's diseasesource ↗
◆Oral PresentationGT-04686Presentation
New series of GCase allosteric modulators presented at AD/PD 2026
Parkinson's diseasesource ↗
●IND Enabling CompleteGT-04686Preclinical
GT-04686 ready for IND-enabling studies
Parkinson's diseasesource ↗
◆Oral PresentationPresentation
Fireside chat at Oppenheimer 36th Annual Healthcare Life Sciences Conference
◆Oral PresentationGT-02287Presentation
Virtual KOL event to discuss Phase 1b results
Parkinson's diseasesource ↗
▲Full ResultsGT-02287Clinical Data
Additional biomarker and clinical data from Phase 1b study of GT-02287
Parkinson's diseasesource ↗
▲Trial InitiationGT-02287Trial
Phase 1b study extension commenced allowing up to 12 months treatment
Parkinson's diseasesource ↗
▲Enrollment CompleteGT-02287Trial
Completed enrollment in Phase 1b nine-month extension for GT-02287
Parkinson's diseasesource ↗
●IND SubmissionGT-02287IND
IND submission for Phase 2 planning of GT-02287
Parkinson's diseasesource ↗
▲Full ResultsGT-02287Clinical Data
Positive results in key exploratory endpoint: reduction in GluSph in CSF
Parkinson's diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How GANX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-04 | rexaceract (GT-02287) | Phase 1b data presentation | Phase 1b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D26 / 100
Pipeline Score
$9M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 80%
Micro Cap(rank 527 of 658)
Percentile Rank
Gain Therapeutics, Inc. faces pipeline headwinds (26/100), with $241M risk-adjusted pipeline value, led by GT-02287 in Parkinson Disease (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GT-02287 Small moleculeNCT07280299 | Parkinson Disease | Phase 2 | NOT YET_RECRUITING | 131 | Jun 30, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every GANX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| rexaceract | Parkinson's disease | Phase 1b | 2026-10-01 | MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration of rexaceract.Read More | Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months AdministrationRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| GOLDSTEIN DOV A MDDirector | Grant/Award | 25,000 25,000 held | $0.00 | 07/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GANX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in GANX for Q2 2026. | ||||
GANX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-02-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GANX ranks across every disease it competes in
Competitive Position is a premium feature
See how GANX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGANX News
GANX▼ -3.3%today
Gain Therapeutics to Attend the 2026 Maxim Growth Summit
Gain Therapeutics, Inc. will participate in the 2026 Maxim Growth Summit from October 12-14 in New York City. The company aims to connect with institutional investors and engage in discussions with senior analysts. The summit will feature prominent speakers and cover various sectors, including biotechnology and technology.
Read more →GANXGain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
Gain Therapeutics presented positive data from a Phase 1b open-label extension study of rexaceract, showing stabilization of MDS-UPDRS motor scores in participants with Parkinson's disease over 12 months. The results indicate a favorable safety profile and support the drug's disease-modifying potential. The company plans to submit a new Phase 2 study protocol to the FDA and initiate the trial in early 2027.
Read more →GANXGain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders
Gain Therapeutics, Inc. announced a poster presentation at the International Congress of Parkinson's Disease and Movement Disorders, scheduled for October 4-8, 2026, in Seoul, Korea. The presentation will focus on long-term data for their drug candidate, rexaceract, which is in clinical development for Parkinson's disease. The company has received funding from various foundations to support this research.
Read more →GANXGain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
Gain Therapeutics, Inc. announced its participation in the ROTH Fifth Annual Healthcare Opportunities Conference, where CEO Gene Mack will engage in a panel discussion and one-on-one meetings. The conference will take place on September 29, 2026, in New York. Gain's lead drug candidate, rexaceract, is currently in a Phase 1b trial for Parkinson's disease, with potential applications in other neurodegenerative disorders.
Read more →GANXGain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
Gain Therapeutics, Inc. will participate in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. CEO Gene Mack will engage in one-on-one meetings, and a presentation will be available on-demand starting September 11. The company is focused on developing allosteric therapies, including its lead candidate, rexaceract, for Parkinson's disease.
Read more →GANX▲ +16.4%on this news
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
Gain Therapeutics reported its financial results for Q2 2026, highlighting FDA authorization for its drug rexaceract to advance into Phase 2 clinical development. The company shared positive clinical data supporting the drug's potential in treating Parkinson's disease. Additionally, management changes were announced to enhance leadership. However, the company reported a net loss and a decrease in cash reserves.
Read more →GANXGain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
Gain Therapeutics has provided an operational update highlighting progress in the clinical development of its lead drug candidate, rexaceract, for Parkinson's disease. The company has received IND authorization and plans to initiate a Phase 2 study in late 2026. Early data from ongoing trials show promising safety and efficacy results, with further updates expected later this year.
Read more →GANXGain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
Gain Therapeutics has received FDA clearance for its IND application to advance GT-02287 into Phase 2 clinical development for Parkinson's disease. This decision follows positive Phase 1 results indicating both safety and efficacy. The Phase 2 study is expected to begin in the third quarter of 2026, involving participants from the U.S., Australia, and Europe.
Read more →GANXGain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
Gain Therapeutics, Inc. will present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on June 15-16, 2026. CEO Gene Mack will engage in a virtual fireside chat and one-on-one meetings. The company is focused on developing allosteric therapies, with its lead candidate GT-02287 currently in a Phase 1b trial for Parkinson's disease.
Read more →GANXGain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
Gain Therapeutics has presented encouraging interim data from its Phase 1b clinical study of GT-02287 at the 3rd International GBA1 Meeting. The study demonstrated that MDS-UPDRS scores remained stable after 150 days of treatment, with notable benefits reported by participants in areas such as smell, taste, and balance. Comparisons revealed significant differences in scores between those with low and high baseline glucosylsphingosine levels. The continuing development of GT-02287 aims to address the underlying biology of Parkinson's disease.
Read more →GANXGain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
Gain Therapeutics reported its financial results for Q1 2026, highlighting advancements in its lead candidate GT-02287 for Parkinson's disease. The ongoing Phase 1b study shows promising biomarker data and stable MDS-UPDRS scores. The company anticipates FDA clearance for its IND in Q2 2026, with a Phase 2 study expected to commence in Q3 2026.
Read more →GANXGain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
Gain Therapeutics announced an oral presentation at the 3rd International GBA1 Meeting 2026, highlighting their lead drug candidate, GT-02287, for Parkinson's disease. The drug has shown promising results in preclinical models and is currently in a Phase 1b clinical trial. Initial findings indicate favorable safety, tolerability, and potential disease-modifying effects.
Read more →GANXGain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
Gain Therapeutics reported its financial results for Q4 and the year ending December 31, 2025, highlighting progress in the development of GT-02287 for Parkinson's disease. The company noted stable MDS-UPDRS scores and significant reductions in glucosylsphingosine levels in patients. Looking ahead, they anticipate starting Phase 2 trials in Q3 2026 and have ongoing engagements with the FDA.
Read more →GANXGain Therapeutics to Present at the 38th Annual ROTH Conference
Gain Therapeutics, Inc. announced that its President and CEO, Gene Mack, will participate in a fireside chat and one-on-one meetings at the 38th Annual ROTH Conference from March 22-24, 2026. The company is focused on developing allosteric therapies, with its lead candidate GT-02287 currently in a Phase 1b trial for Parkinson's disease. Gain's unique drug discovery platform aims to address various neurodegenerative and genetic disorders.
Read more →GANX▼ -25.6%on this newsshared move
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
Gain Therapeutics presented additional clinical and biomarker data on GT-02287 at the AD/PD 2026 conference. The Phase 1b study indicated a reduction in glucosylsphingosine levels and stable MDS-UPDRS scores after continued treatment. Additionally, preclinical data from a new chemical series, led by GT-04686, was revealed as it prepares for IND-enabling studies for Parkinson's disease. Both the ongoing trial and the novel compounds suggest promising avenues for disease modification in managing Parkinson's disease.
Read more →GANXGain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
Gain Therapeutics announced its participation in the AD/PD 2026 conference, where it will present findings from its Phase 1b study of GT-02287 for Parkinson's disease. The company is also preparing to initiate a Phase 2 clinical trial after submitting additional data to the FDA. The drug candidate aims to modify disease progression rather than just alleviate symptoms.
Read more →GANXGain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Gain Therapeutics, Inc. will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, which takes place on February 25-26, 2026. The company management will engage in a fireside chat and individual meetings with attendees to discuss their advancements in allosteric small molecule therapies. Notably, Gain's lead candidate, GT-02287, is being evaluated for Parkinson's disease in a Phase 1b clinical trial, with potential applications in other neurodegenerative conditions. For those unable to attend, Gain has provided alternative meeting arrangements for investor communication.
Read more →GANXCorporate Presentation September 2024 GAIN THERAPEUTICS Corporate Deck February 2026 NASDAQ: GANX © © 2 0 2 6 2 0 2 5 - -G AG A I N T H E R A P E U T I C S I N T H E R A P E U T I C S 22 Certain statements set
GAIN Therapeutics has released a corporate presentation detailing the progress of their investigational drug GT-02287 for Parkinson's disease. The ongoing Phase 1b trial has shown promising results, with patients experiencing significant reductions in glucosylceramide levels and improvements in clinical measures such as the MDS-UPDRS scores. The study evaluates the safety and efficacy of the drug, with plans for a Phase 2 trial set to initiate in the second half of 2026, further investigating the drug's tolerability and biological effects. The company is well-supported by various research foundations and maintains a solid financial position.
Read more →GANX▼ -5.5%on this news· ran to -16% by day 3
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
Gain Therapeutics, Inc. announced its participation in several conferences during the J.P. Morgan Healthcare Conference week, including the Sachs Neuroscience Innovation Forum and the Biotech Showcase. The company is advancing its lead drug candidate, GT-02287, which is in a Phase 1b clinical trial for Parkinson's disease. GT-02287 has shown potential in preclinical models and has received funding support from various foundations.
Read more →About Gain Therapeutics, Inc.
Headquarters4800 HAMPDEN LANE, BETHESDA, MD, 20814
BIOPHARMAWATCH ELITE PLUS
Trade the next GANX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime